“…The design and synthesis of new organotin carboxylates by selecting ligands and organotin substrates has been encouraged in order to achieve efficacy. 2,6-pyridinedicarboxylic acid (Scheme 1) is a dicarboxylic acid containing an aromatic N donor atom, and some of its di-and trioganotin derivatives such as R 2 Sn(2,6-C 5 H 3 N)(COO) 2 (H 2 O) (R = Me, n-Bu) (Szorcsik et al, 2004a;Azadmeher et al, 2008), R 2 Sn(2,6-C 5 H 3 N)(COO) 2 (R = t-Bu, Ph, Et) (Gielen, 2002;Szorcsik et al, 2004b), 2,6-C 5 H 3 N(COOSnBu-n 3 ) 2 (Yin et al, 2007), 2,6-C 5 H 3 N(COOSnBu-n 3 ) 2 (4,4′-bpy) (Chandrasekhar et al, 2012) have been studied. In order to continue to expand the chemistry and therapeutic potential of the triorganotin/2,6-pyridinedicarboxylic acid compounds, we synthesized two new bis(triorganotin) 2,6-pyridinedicarboxylates from 2,6-pyridinedicarboxylic acid and triorganotin hydroxide and determined their in vitro cytotoxic activity.…”